Evidence map›Paper›PMID 42656976›Full record

ArticleResearch and practice in thrombosis and haemostasis2026

Beyond complement: comprehensive assessment of factor XIII plasma dynamics and genetics in atypical hemolytic uremic syndrome.

Noémi Janszky, Éva Katona, György Sinkovits, Dorottya Csuka, Ágnes Haris, Velibor Tasic, Nora Abazi-Emini, Christof Aigner, Alice Schmidt, Gere Sunder-Plassmann and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Research and practice in thrombosis and haemostasis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Noémi JanszkyResearch Laboratory, Department of Internal Medicine and Haematology, Semmelweis University, Budapest, Hungary.
Éva KatonaDivision of Clinical Laboratory Science, Department of Laboratory Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
György SinkovitsResearch Laboratory, Department of Internal Medicine and Haematology, Semmelweis University, Budapest, Hungary.
Dorottya CsukaResearch Laboratory, Department of Internal Medicine and Haematology, Semmelweis University, Budapest, Hungary.
Ágnes HarisDepartment of Internal Medicine and Nephrology, Budapesti Péterfy Hospital-Outpatient Clinic, Budapest, Hungary.
Velibor TasicMedical Faculty Skopje, University Children's Hospital, Skopje, North Macedonia.
Nora Abazi-EminiMedical Faculty Skopje, University Children's Hospital, Skopje, North Macedonia.
Christof AignerDivison of Nephrology and Dialysis, Department of Medicine III, Medical University Vienna, Vienna, Austria.
Alice SchmidtDivison of Nephrology and Dialysis, Department of Medicine III, Medical University Vienna, Vienna, Austria.
Gere Sunder-PlassmannDivison of Nephrology and Dialysis, Department of Medicine III, Medical University Vienna, Vienna, Austria.
Silvie Rajnochová BloudíčkováDepartment of Nephrology, Transplant Center, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
Zoltán ProhászkaResearch Laboratory, Department of Internal Medicine and Haematology, Semmelweis University, Budapest, Hungary.
László MuszbekDivision of Clinical Laboratory Science, Department of Laboratory Medicine, Faculty of Medicine, University of Debrecen, Debrecen, Hungary.
Ágnes SzilágyiResearch Laboratory, Department of Internal Medicine and Haematology, Semmelweis University, Budapest, Hungary.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Atypical hemolytic uremic syndrome (aHUS) is a distinct form of thrombotic microangiopathy characterized by formation of fibrin-rich thrombi. Factor XIII (FXIII), a key fibrin-stabilizing enzyme, may therefore represent an unexplored contributor to the pathophysiology of aHUS, and a comprehensive evaluation of its plasma dynamics and genetic background is lacking. Objectives: This study aimed to evaluate plasma FXIII levels and Methods: The cohort comprised 102 patients with aHUS and 73 healthy controls. FXIII activity was measured by ammonia release assay, FXIII antigen levels by ELISA, and Results: FXIII activity was decreased in aHUS patients during the acute phase (median 72.8%; IQR, 52.8%-121.0%) versus those in remission (123.1%; IQR, 97.9%-156.3%; Conclusion: This comprehensive genetic and plasma study of FXIII in aHUS argues against it having a causal role, while the remission-associated increase in free FXIII-B supports it as a promising biomarker candidate for this rare but severe disease.

Indexed as

Atypical Hemolytic Uremic SyndromeFactor XIIIAdolescentAdultCase-Control StudiesChildFemaleGenetic Predisposition to DiseaseHumansMaleYoung AdultFactor XIIIfactor XIIIbatypical haemolytic uraemic syndromeblood coagulation factorsfactor XIIIFXIII-B subunitgenetic variation

Identifiers

PMID42656976
PMCPMC13508634

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.